Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis

/PRNewswire/ -- Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful...

Related Keywords

Miami ,Florida ,United States ,Tarrytown ,Japan ,Paris ,France General ,France ,University Of Miami ,American ,Gil Yosipovitch ,Georged Yancopoulos ,Regeneron Velocimmune ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,Dupilumab Development Program ,Regeneron Velocimmune Technology ,Nasdaq ,Teva Pharmaceutical Industries Ltd ,Exchange Commission ,Miami Itch Center ,American Academy Of Dermatology ,Euronext ,American Academy ,Miller School ,About Prurigo ,Worst Itch Numeric Rating Scale ,Global Assessment ,Chief Scientific Officer George ,Prescribing Informationincluding Patient ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Teva Pharmaceutical Industries ,Nc ,Biotechnology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,